Aptamer Sciences Inc (291650) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Aptamer Sciences Inc stock KRW 1,598, price KRW 2,180, that is 26.7% below the price, quality 42 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Aptamer Sciences Inc
291650 · KQExpensive (fair value 27% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range 950.00 KRW – 21,413 KRW · fair‑value band 1,199 KRW – 1,998 KRW · the 2,180 KRW price screens above the 1,598 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Aptamer Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Aptamer Sciences Inc, a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms.
Show moreShow less
The company's platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics for cancer and neurological disorders.
It offers AlloMAp and Bi-Functional Aptame (BiFAp) platform programs for therapeutics, as well as Aptodetect-lung, an early diagnosis kit for lung cancer. Aptamer Sciences Inc was founded in 2011 and is headquartered in Seongnam-si, South Korea.
Stock analysis
Aptamer Sciences Inc (291650) currently trades at 2,180 KRW, while our estimate is 1,598 KRW, 27% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 1,199 KRW (bear) to 1,998 KRW (bull), the price of 2,180 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Aptamer Sciences Inc reported revenue of 3.5B KRW in FY2025 versus 269M KRW in FY2021, a compound +89.9%/yr. Reported net income was −8.6B KRW in FY2025.
Key figures
Market cap 114B KRW (≈ $85.2M) Micro · P/S ratio 66.9 · Return on equity −42.5% · Return on assets (EBIT) −21.7% (5-year average) · Operating margin −129% · Revenue growth (YoY) +292% · Free cash flow −9.7B KRW · Net debt 7.0B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 44% below its 52-week high and 129% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −27%, 291650 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Aptamer Sciences Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs 291650 |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs 291650 |
| Samsung Biologics Co 207940 | 1,414,000 KRW | 1,552,100 KRW | +10% | vs 291650 |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs 291650 |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs 291650 |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs 291650 |
| BeOne Medicines AG 6160 | HK$247.40 | HK$152.92 | −38% | vs 291650 |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs 291650 |
| Celltrion, Inc 068270 | 213,000 KRW | 74,945 KRW | −65% | vs 291650 |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs 291650 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Aptamer Sciences Inc (291650) overvalued or undervalued?
What is the fair value of 291650?
What is the quality score of 291650?
What is the price target for Aptamer Sciences Inc (291650)?
What is the Aptamer Sciences Inc stock forecast for 2026?
What is the intrinsic value of Aptamer Sciences Inc (291650)?
Is Aptamer Sciences Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 291650?
How much is Aptamer Sciences Inc worth?
What do the bullish and bearish scenarios say about 291650?
How solid is the balance sheet of Aptamer Sciences Inc (291650)?
How far is 291650 from its 52-week high?
Which stocks are comparable to Aptamer Sciences Inc?
Is Aptamer Sciences Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Aptamer Sciences Inc (291650)?
What should I pay attention to with Aptamer Sciences Inc right now?
Key figures of Aptamer Sciences Inc
How large is the market capitalisation of Aptamer Sciences Inc (291650)?
What is the P/S ratio of Aptamer Sciences Inc (291650)?
What is the return on equity of Aptamer Sciences Inc (291650)?
What is the EBIT return on assets of Aptamer Sciences Inc (291650)?
What is the operating margin of Aptamer Sciences Inc (291650)?
How fast is revenue growing at Aptamer Sciences Inc (291650)?
How much free cash flow does Aptamer Sciences Inc (291650) generate?
How much net debt does Aptamer Sciences Inc (291650) carry?
Watch Aptamer Sciences Inc in the live analysis
One click puts Aptamer Sciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.